DefinePK

Abstract

Equitable access to essential medicines remains one of the most pressing global health challenges of the twenty-first century. Despite scientific and technological advances in drug development, millions in low- and middle-income countries (LMICs) still face barriers to affordable and timely treatment. This gap between innovation and accessibility—often driven by fragmented data systems, weak regulatory infrastructures, and market inefficiencies—underscores the need for pharmaceutical market analytics as a strategic tool for achieving therapeutic equity.
This manuscript explores how data-driven models can transform medicine availability, affordability, and distribution through predictive analytics, real-time demand forecasting, and adaptive pricing algorithms. By leveraging artificial intelligence (AI) and real-world data, market analytics can identify underserved populations, optimize supply chains, and inform fair pricing mechanisms. Furthermore, the paper proposes a framework for ethical and equitable pharmaceutical market intelligence that integrates analytics, policy, and governance to ensure transparency and sustainability. Case examples from global access initiatives, such as insulin distribution programs and the WHO Global Price Reporting Mechanism, illustrate how analytics can close existing equity gaps.
Ultimately, this paper argues that the future of pharmaceutical access depends not only on innovation in science but also on innovation in data systems—where evidence-based analytics empower stakeholders to design inclusive and resilient health markets. The findings highlight the critical intersection between data science, policy, and ethics in achieving universal access to essential medicines.
Keywords: Pharmaceutical Analytics, Therapeutic Equity, Market Access.